232 related articles for article (PubMed ID: 33827546)
1. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia).
Elliott JW; Swinbourne F; Parry A; Baines L
J Small Anim Pract; 2017 Jul; 58(7):416-418. PubMed ID: 28199021
[TBL] [Abstract][Full Text] [Related]
4. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of KIT during clonal expansion and subsequent acquisition of resistance to toceranib in a canine mast cell tumor cell line.
Kurita S; Miyamoto R; Tani H; Kobayashi M; Sasaki T; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2019 Nov; 42(6):673-681. PubMed ID: 31553064
[TBL] [Abstract][Full Text] [Related]
6. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Leblanc AK; Miller AN; Galyon GD; Moyers TD; Long MJ; Stuckey AC; Wall JS; Morandi F
Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
[TBL] [Abstract][Full Text] [Related]
7. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine.
Weishaar KM; Ehrhart EJ; Avery AC; Charles JB; Elmslie RE; Vail DM; London CA; Clifford CA; Eickhoff JC; Thamm DH
J Vet Intern Med; 2018 Jan; 32(1):394-405. PubMed ID: 29194765
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
Lew FH; McQuown B; Borrego J; Cunningham S; Burgess KE
Vet Comp Oncol; 2019 Dec; 17(4):465-471. PubMed ID: 31069932
[TBL] [Abstract][Full Text] [Related]
9. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
Musser ML; Johannes CM
BMC Vet Res; 2021 Aug; 17(1):269. PubMed ID: 34380474
[TBL] [Abstract][Full Text] [Related]
10. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.
Urie BK; Russell DS; Kisseberth WC; London CA
BMC Vet Res; 2012 May; 8():67. PubMed ID: 22630170
[TBL] [Abstract][Full Text] [Related]
12. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
13. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
[TBL] [Abstract][Full Text] [Related]
14. Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.
Halsey CH; Gustafson DL; Rose BJ; Wolf-Ringwall A; Burnett RC; Duval DL; Avery AC; Thamm DH
BMC Vet Res; 2014 May; 10():105. PubMed ID: 24885200
[TBL] [Abstract][Full Text] [Related]
15. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
[TBL] [Abstract][Full Text] [Related]
16. Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.
Remerowski SM; Herrera CL; Donnelly LL
BMC Vet Res; 2021 Apr; 17(1):146. PubMed ID: 33827545
[TBL] [Abstract][Full Text] [Related]
17. Toceranib phosphate in the treatment of canine thyroid carcinoma: 42 cases (2009-2018).
Sheppard-Olivares S; Bello NM; Wood E; Szivek A; Biller B; Hocker S; Wouda RM
Vet Comp Oncol; 2020 Dec; 18(4):519-527. PubMed ID: 32012432
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017).
Musser ML; Taikowski KL; Johannes CM; Bergman PJ
BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Bernabe LF; Portela R; Nguyen S; Kisseberth WC; Pennell M; Yancey MF; London CA
BMC Vet Res; 2013 Sep; 9():190. PubMed ID: 24079884
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM
J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]